AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 22.93 |
| Open | 23.03 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 3200 |
| Day's Range | 22.54 - 23.50 |
| 52 Week Range | 11.93 - 26.10 |
| Volume | 332,990 |
| Avg. Volume | 597,587 |
| Market Cap | 786.669M |
| Beta (3Y Monthly) | -0.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.43 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.75 |
- GlobeNewswire•5 days ago
Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•13 days ago
Is the Options Market Predicting a Spike in AMAG Pharmaceuticals (AMAG) Stock?
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
- Zacks•17 days ago
New Strong Sell Stocks for October 5th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Market Realist•17 days agoMakena Auto Injector Is a Key Asset for Antares Pharma in 2018
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.
Market Realist•18 days agoAntares Pharma Could Report Solid Revenue Growth in Fiscal 2018
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.
- GlobeNewswire•18 days ago
AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone
AMAG Pharmaceuticals, Inc. (AMAG) and Endoceutics today announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone (INTRAROSA®) at the Annual Meeting of The North American Menopause Society (NAMS) in San Diego, California. David F. Archer, M.D., NCMP, will present the study results on Thursday, October 4th from 5:15 PM to 5:30 PM. Dr. Archer and colleagues analyzed combined data obtained from two prospective, randomized, double-blind, placebo-controlled clinical trials to evaluate the effect of daily intravaginal 6.5 mg INTRAROSA administered for 12 weeks to women who identified moderate to severe pain at sexual activity (dyspareunia) as their most bothersome symptom (MBS) of vulvar and vaginal atrophy, or VVA.
- Zacks•25 days ago
AMAG In-Licenses Global Rights to Orphan Drug Candidate
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
- GlobeNewswire•26 days ago
AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women. AMAG and Velo Bio, LLC, a privately held life sciences company located in the Research Triangle Park region of North Carolina, entered into an option agreement in July 2015 to develop DIF.
- GlobeNewswire•last month
AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a Conversation About an Often Unrecognized and Untreated Medical Condition, Painful Sex Due to Menopause
AMAG Pharmaceuticals, Inc. (AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and menopause expert, Marla Shapiro, MD, it is launching an integrated campaign to start an open dialogue about painful sex due to menopause, a topic that is often not talked about among post-menopausal women and their healthcare providers. Vulvar and vaginal atrophy, or VVA, affects approximately 50 percent of postmenopausal women in the United States, and painful sex is one of the potential symptoms.1 Unlike more commonly known symptoms of menopause, such as hot flashes, many women are not aware that painful sex is associated with menopause.
- PR Newswire•last month
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results
Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J. , Sept. 13, 2018 /PRNewswire/ ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes
AMAG Pharmaceuticals, Inc. (AMAG) today announced that it has redeemed $475 million of its outstanding 7.875% senior notes, using the proceeds from the sale of Cord Blood Registry®, which closed on August 6, 2018. “Through the payment of our senior notes, which eliminates nearly $40 million in annual cash interest expense, as well as the early retirement of the $320 million term loan in May 2017, we have dramatically improved our financial profile,” said Ted Myles, AMAG’s chief financial officer. AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs.
- Zacks•2 months ago
Options Traders Expect Huge Moves in AMAG Pharmaceuticals (AMAG) Stock
AMAG Pharmaceuticals (AMAG) needs investors to pay close attention to the stock based on moves in the options market lately.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AMAG earnings conference call or presentation 2-Aug-18 12:00pm GMT
Q2 2018 AMAG Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 23, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. B. Riley FBR Healthcare Conference Tuesday, September ...
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within AMAG Pharmaceuticals, Pier 1 Imports, Gogo, IDT, Axalta Coating, and Sprouts Farmers Market — New Research Emphasizes Economic Growth
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMAG ...
- PR Newswire•2 months ago
California Cryobank And Cord Blood Registry Combine To Create A Leading Life Sciences Platform
LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- California Cryobank , the world's leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Completes Divestiture of Cord Blood Registry®
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. The purchase price is subject to customary purchase price adjustments with respect to working capital, cash, indebtedness and transaction expenses as previously disclosed. “Completing the divestiture of CBR is an important step in the successful execution of AMAG’s strategic plan which focuses on growing and diversifying our pharmaceutical business,” said William Heiden, president and chief executive officer at AMAG.
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development.
- Zacks•3 months ago
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -257.14% and -6.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
AMAG Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 58 cents. Losses, adjusted to account for discontinued operations, were 75 cents per share. The results fell short of ...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Achieved 12% revenue growth and record quarterly sales. Raising full year revenue and adjusted EBITDA guidance for pharmaceutical products. Conference call scheduled for 8:00 a.m. ET today.
- ACCESSWIRE•3 months ago
AMAG Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2, 2018 at 8:00 a.m. ET
WALTHAM, Mass., July 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its second quarter 2018 financial results will be released on Thursday, August 2, 2018 before the U.S. financial markets ...
- Moody's•3 months ago
GI Chill Acquisition LLC -- Moody's assigns a B3 CFR to GI Chill Acquisition LLC; stable outlook
Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.
